University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 3 of 16
Effect of Cooling Therapy for Post-Operative Pain in Open Carpal Tunnel Release
NCT05783245
Interactive Computer-adaptive Chronic Kidney Disease Education Program
NCT06364358
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
NCT05789303
LH Canine Therapy Study
NCT05840198
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
NCT05710380
Tocilizumab for Acute Chest Syndrome
NCT05640271
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
NCT05526924
Predict Severe Traumatic Brain Injury
NCT06966713
Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
NCT05723653
GI Oxalate Absorption
NCT05356000
At-home Walking Cadence Functional Assessment and Recovery Trajectory for Older Adults Undergoing Major Surgery
NCT05886725
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
NCT05166694
Oxalate and Citrate
NCT05334979
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
NCT05420948
Case Management Dyad
NCT06162897
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT05200442
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
NCT05068232
Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
NCT05512754
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
NCT05264051
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT05608694
The Reducing REVISITS Study: A Cluster RCT
NCT05568043
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
NCT04541381
Diabetic Neuropathy in Spinal Cord Stimulator Patients
NCT04687215
Nitrous Oxide as Treatment for Fibromyalgia
NCT05357066
Reducing Opioid Mortality in Illinois
NCT04925427
Antidepressant Effects of Nitrous Oxide
NCT05357040
Variable Immobilization Protocol for Arthroplasty of the Carpometacarpal Joint of the Thumb
NCT04828954
Intermuscular Coherence as a Biomarker for ALS
NCT05104710
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
NCT04747912
Olaparib in Patients With HRD Malignant Mesothelioma
NCT04515836
Aspirin and Preeclampsia
NCT04479072
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04683653
Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT04705038
Gut Microbiome and Sex as Risk Factors for Kidney Stones After Bariatric Surgery
NCT04590690
Detecting HPV DNA in Anal and Cervical Cancers
NCT04857528
Efficacy Of Hiatal Closure For GERD
NCT06280664
Point of Care Testing for Presence of Current and or Previous T. Gondii Infection
NCT04474132
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
NCT04295863
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
NCT04361708
Mechanisms of Prediabetic States in Sleep Apnea
NCT04234217
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT03729115
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321
Comprehensive Care Community and Culture Study
NCT04489693
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
NCT03901924
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
NCT03729180
Forceps vs. Snare IVC Filter Removal
NCT04092192
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
NCT03326310
Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
NCT03225820
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02366819
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
NCT02333162
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Chicago pipeline card: 796 registered trials from official public datasets.Report a data error.